TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Trial of Postplacental or Delayed Insertion of the Levonorgestrel-releasing Intrauterine Device After Vaginal Delivery
Brief Summary: This study is a randomized controlled trial comparing 6 month usage rates of the levonorgestrel-releasing intrauterine device (LNG-IUD) when inserted postplacentally after vaginal delivery or delayed placement at 6-8 weeks postpartum. Given the high rate of unintended pregnancy in the United States, particularly in postpartum women, there is a need for reliable, effective, long-term contraception such as the IUD in postpartum women. Postplacental insertion of intrauterine contraception would help to address this need. The primary hypothesis of this study is that use of the LNG-IUD at 6 months after vaginal delivery will be higher in women who have immediate postplacental insertion as compared to delayed insertion 6-8 weeks following delivery.


Options:
A: Arm Label: Immediate Postplacental; Type: EXPERIMENTAL; Interventions: Device: Levonorgestrel Intrauterine System (LNG-IUS: Mirena, Bayer) | Arm Label: Early Postpartum; Type: EXPERIMENTAL; Interventions: Device: Levonorgestrel Intrauterine System (LNG-IUS: Mirena, Bayer) | Arm Label: Interval; Type: EXPERIMENTAL; Interventions: Device: Levonorgestrel Intrauterine System (LNG-IUS: Mirena, Bayer) | Intervention Type: DEVICE; Name: Levonorgestrel Intrauterine System (LNG-IUS: Mirena, Bayer); Assigned to Arm(s): Early Postpartum, Immediate Postplacental, Interval
B: Arm Label: postplacental insertion after cesarean; Type: EXPERIMENTAL; Interventions: Device: Levonorgestrel-releasing intrauterine system (LNG-IUS) | Arm Label: delayed insertion group; Type: ACTIVE_COMPARATOR; Interventions: Device: Levonorgestrel-releasing intrauterine system (LNG-IUS) | Intervention Type: DEVICE; Name: Levonorgestrel-releasing intrauterine system (LNG-IUS); Assigned to Arm(s): postplacental insertion after cesarean | Intervention Type: DEVICE; Name: Levonorgestrel-releasing intrauterine system (LNG-IUS); Assigned to Arm(s): delayed insertion group
C: Arm Label: Postplacental IUD insertion; Type: EXPERIMENTAL; Interventions: Device: Levonorgestrel-releasing IUD (Mirena) | Arm Label: Delayed IUD insertion; Type: ACTIVE_COMPARATOR; Interventions: Device: Levonorgestrel-releasing IUD (Mirena) | Intervention Type: DEVICE; Name: Levonorgestrel-releasing IUD (Mirena); Assigned to Arm(s): Delayed IUD insertion, Postplacental IUD insertion
D: Arm Label: Immediate postpartum IUD insertion; Type: EXPERIMENTAL; Interventions: Device: Copper T380A Intrauterine Device | Arm Label: 6 week postpartum IUD insertion; Type: EXPERIMENTAL; Interventions: Device: Copper T380A Intrauterine Device | Intervention Type: DEVICE; Name: Copper T380A Intrauterine Device; Assigned to Arm(s): 6 week postpartum IUD insertion, Immediate postpartum IUD insertion

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Trial of Postplacental or Delayed Insertion of the Levonorgestrel-releasing Intrauterine Device After Vaginal Delivery
Brief Summary: This study is a randomized controlled trial comparing 6 month usage rates of the levonorgestrel-releasing intrauterine device (LNG-IUD) when inserted postplacentally after vaginal delivery or delayed placement at 6-8 weeks postpartum. Given the high rate of unintended pregnancy in the United States, particularly in postpartum women, there is a need for reliable, effective, long-term contraception such as the IUD in postpartum women. Postplacental insertion of intrauterine contraception would help to address this need. The primary hypothesis of this study is that use of the LNG-IUD at 6 months after vaginal delivery will be higher in women who have immediate postplacental insertion as compared to delayed insertion 6-8 weeks following delivery.


Options:
A: Arm Label: Study Arm A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Combined estrogen-progestin pill | Arm Label: Study Arm B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Progestin-only pill | Intervention Type: DRUG; Name: Combined estrogen-progestin pill; Assigned to Arm(s): Study Arm A | Intervention Type: DRUG; Name: Progestin-only pill; Assigned to Arm(s): Study Arm B
B: Arm Label: Postplacental IUD insertion; Type: EXPERIMENTAL; Interventions: Device: Levonorgestrel-releasing IUD (Mirena) | Arm Label: Delayed IUD insertion; Type: ACTIVE_COMPARATOR; Interventions: Device: Levonorgestrel-releasing IUD (Mirena) | Intervention Type: DEVICE; Name: Levonorgestrel-releasing IUD (Mirena); Assigned to Arm(s): Delayed IUD insertion, Postplacental IUD insertion
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Etonogestrel contraceptive implant | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Etonogestrel contraceptive implant | Intervention Type: DRUG; Name: Etonogestrel contraceptive implant; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Etonogestrel contraceptive implant; Assigned to Arm(s): 2
D: Arm Label: etonogestrel implant; Type: EXPERIMENTAL; Interventions: Drug: etonogestrel implant | Arm Label: depot medroxyprogesterone acetate; Type: ACTIVE_COMPARATOR; Interventions: Drug: depot medroxyprogesterone acetate | Intervention Type: DRUG; Name: etonogestrel implant; Assigned to Arm(s): etonogestrel implant | Intervention Type: DRUG; Name: depot medroxyprogesterone acetate; Assigned to Arm(s): depot medroxyprogesterone acetate

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: Open, parallel group design. The study has a screening phase and a 12 week treatment phase. Subjects will be randomised to treatment in a 1:1 ration.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Budesonide / formoterol fumarate (SYMBICORT) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Budesonide | Intervention Type: DRUG; Name: Budesonide / formoterol fumarate (SYMBICORT); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Budesonide; Assigned to Arm(s): 2
B: Intervention Type: DRUG; Name: FLUTIFORM® (Formoterol fumarate / Fluticasone propionate); Assigned to Arm(s): N/A
C: Arm Label: ADVAIR 100/50mcg; Type: EXPERIMENTAL; Interventions: Drug: ADVAIR 100/50mcg | Arm Label: ADVAIR 250/50mcg; Type: EXPERIMENTAL; Interventions: Drug: ADVAIR 250/50mcg | Arm Label: ADVAIR 500/50mcg; Type: EXPERIMENTAL; Interventions: Drug: ADVAIR 500/50mcg | Arm Label: FLOVENT 100mcg; Type: ACTIVE_COMPARATOR; Interventions: Drug: FLOVENT 100mcg | Arm Label: FLOVENT 250mcg; Type: ACTIVE_COMPARATOR; Interventions: Drug: FLOVENT 250mcg | Arm Label: FLOVENT 500mcg; Type: ACTIVE_COMPARATOR; Interventions: Drug: FLOVENT 500mcg | Intervention Type: DRUG; Name: ADVAIR 100/50mcg; Assigned to Arm(s): ADVAIR 100/50mcg | Intervention Type: DRUG; Name: ADVAIR 250/50mcg; Assigned to Arm(s): ADVAIR 250/50mcg | Intervention Type: DRUG; Name: ADVAIR 500/50mcg; Assigned to Arm(s): ADVAIR 500/50mcg | Intervention Type: DRUG; Name: FLOVENT 100mcg; Assigned to Arm(s): FLOVENT 100mcg | Intervention Type: DRUG; Name: FLOVENT 250mcg; Assigned to Arm(s): FLOVENT 250mcg | Intervention Type: DRUG; Name: FLOVENT 500mcg; Assigned to Arm(s): FLOVENT 500mcg
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: budesonide/formoterol (Symbicort) | Intervention Type: DRUG; Name: budesonide/formoterol (Symbicort); Assigned to Arm(s): 1

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: Open, parallel group design. The study has a screening phase and a 12 week treatment phase. Subjects will be randomised to treatment in a 1:1 ration.


Options:
A: Arm Label: MF/F MDI 200/10 mcg BID; Type: EXPERIMENTAL; Interventions: Drug: Mometasone furoate/formoterol (MF/F) MDI | Arm Label: F/SC DPI 250/50 mcg BID; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fluticasone propionate/salmeterol (F/SC) DPI | Intervention Type: DRUG; Name: Mometasone furoate/formoterol (MF/F) MDI; Assigned to Arm(s): MF/F MDI 200/10 mcg BID | Intervention Type: DRUG; Name: Fluticasone propionate/salmeterol (F/SC) DPI; Assigned to Arm(s): F/SC DPI 250/50 mcg BID
B: Intervention Type: DRUG; Name: FLUTIFORM® (Formoterol fumarate / Fluticasone propionate); Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: beclomethasone dipropionate plus formoterol fumarate combination; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: fluticasone propionate plus salmeterol xinafoate combination; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: budesonide/formoterol (Symbicort) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: fluticasone/salmeterol (Advair) | Intervention Type: DRUG; Name: budesonide/formoterol (Symbicort); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: fluticasone/salmeterol (Advair); Assigned to Arm(s): 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: Open, parallel group design. The study has a screening phase and a 12 week treatment phase. Subjects will be randomised to treatment in a 1:1 ration.


Options:
A: Intervention Type: DRUG; Name: FLUTIFORM® (Formoterol fumarate / Fluticasone propionate); Assigned to Arm(s): N/A
B: Arm Label: ADVAIR 100/50mcg; Type: EXPERIMENTAL; Interventions: Drug: ADVAIR 100/50mcg | Arm Label: ADVAIR 250/50mcg; Type: EXPERIMENTAL; Interventions: Drug: ADVAIR 250/50mcg | Arm Label: ADVAIR 500/50mcg; Type: EXPERIMENTAL; Interventions: Drug: ADVAIR 500/50mcg | Arm Label: FLOVENT 100mcg; Type: ACTIVE_COMPARATOR; Interventions: Drug: FLOVENT 100mcg | Arm Label: FLOVENT 250mcg; Type: ACTIVE_COMPARATOR; Interventions: Drug: FLOVENT 250mcg | Arm Label: FLOVENT 500mcg; Type: ACTIVE_COMPARATOR; Interventions: Drug: FLOVENT 500mcg | Intervention Type: DRUG; Name: ADVAIR 100/50mcg; Assigned to Arm(s): ADVAIR 100/50mcg | Intervention Type: DRUG; Name: ADVAIR 250/50mcg; Assigned to Arm(s): ADVAIR 250/50mcg | Intervention Type: DRUG; Name: ADVAIR 500/50mcg; Assigned to Arm(s): ADVAIR 500/50mcg | Intervention Type: DRUG; Name: FLOVENT 100mcg; Assigned to Arm(s): FLOVENT 100mcg | Intervention Type: DRUG; Name: FLOVENT 250mcg; Assigned to Arm(s): FLOVENT 250mcg | Intervention Type: DRUG; Name: FLOVENT 500mcg; Assigned to Arm(s): FLOVENT 500mcg
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: FOSTER | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Seretide | Intervention Type: DRUG; Name: FOSTER; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Seretide; Assigned to Arm(s): 2
D: Arm Label: Fluticasone Furoate (FF); Type: ACTIVE_COMPARATOR; Interventions: Drug: FF | Arm Label: Fluticasone Furoate /Vilanterol (VI); Type: ACTIVE_COMPARATOR; Interventions: Drug: FF/VI | Arm Label: Fluticasone Furoate/GSK573719; Type: EXPERIMENTAL; Interventions: Drug: FF/GSK573719 | Intervention Type: DRUG; Name: FF/GSK573719; Assigned to Arm(s): Fluticasone Furoate/GSK573719 | Intervention Type: DRUG; Name: FF/GSK573719; Assigned to Arm(s): Fluticasone Furoate/GSK573719 | Intervention Type: DRUG; Name: FF/GSK573719; Assigned to Arm(s): Fluticasone Furoate/GSK573719 | Intervention Type: DRUG; Name: FF/GSK573719; Assigned to Arm(s): Fluticasone Furoate/GSK573719 | Intervention Type: DRUG; Name: FF/GSK573719; Assigned to Arm(s): Fluticasone Furoate/GSK573719 | Intervention Type: DRUG; Name: FF; Assigned to Arm(s): Fluticasone Furoate (FF) | Intervention Type: DRUG; Name: FF/VI; Assigned to Arm(s): Fluticasone Furoate /Vilanterol (VI)

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Yoga on Weight and Fatigue in Breast Cancer Patients Study
Brief Summary: This purpose of this study is to test whether a 6-month yoga program improves quality of life and reduces fatigue and weight gain in breast cancer survivors.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Yoga | Arm Label: 2; Type: OTHER; Interventions: Other: Delayed yoga classes | Intervention Type: BEHAVIORAL; Name: Yoga; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Delayed yoga classes; Assigned to Arm(s): 2
B: Arm Label: 1: exercise with 2 counseling types; Type: EXPERIMENTAL; Interventions: Behavioral: Experimental 1: exercise with 2 counseling types | Arm Label: 2. Usual Care - written materials; Type: OTHER; Interventions: Other: Usual Care - written materials | Intervention Type: BEHAVIORAL; Name: Experimental 1: exercise with 2 counseling types; Assigned to Arm(s): 1: exercise with 2 counseling types | Intervention Type: OTHER; Name: Usual Care - written materials; Assigned to Arm(s): 2. Usual Care - written materials
C: Arm Label: Exercise; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Physical exercise, Other: best supportive care | Arm Label: No exercise; Type: OTHER; Interventions: Other: best supportive care | Intervention Type: BEHAVIORAL; Name: Physical exercise; Assigned to Arm(s): Exercise | Intervention Type: OTHER; Name: best supportive care; Assigned to Arm(s): Exercise, No exercise
D: Arm Label: Group I (yoga-based rehabilitation program); Type: EXPERIMENTAL; Interventions: Procedure: Quality-of-Life Assessment, Procedure: Yoga | Arm Label: Group II (standard care/control); Type: ACTIVE_COMPARATOR; Interventions: Procedure: Quality-of-Life Assessment, Procedure: Yoga | Intervention Type: PROCEDURE; Name: Quality-of-Life Assessment; Assigned to Arm(s): Group I (yoga-based rehabilitation program), Group II (standard care/control) | Intervention Type: PROCEDURE; Name: Yoga; Assigned to Arm(s): Group I (yoga-based rehabilitation program), Group II (standard care/control)

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Yoga on Weight and Fatigue in Breast Cancer Patients Study
Brief Summary: This purpose of this study is to test whether a 6-month yoga program improves quality of life and reduces fatigue and weight gain in breast cancer survivors.


Options:
A: Arm Label: Group (GRP) phone counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Group phone counseling | Arm Label: Mail-based Comparison Condition; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Newsletter | Intervention Type: BEHAVIORAL; Name: Group phone counseling; Assigned to Arm(s): Group (GRP) phone counseling | Intervention Type: BEHAVIORAL; Name: Newsletter; Assigned to Arm(s): Mail-based Comparison Condition
B: Arm Label: Arm I (Control); Type: ACTIVE_COMPARATOR; Interventions: Other: questionnaire administration, Procedure: quality-of-life assessment, Procedure: management of therapy complications | Arm Label: Arm II (Exercise); Type: EXPERIMENTAL; Interventions: Other: questionnaire administration, Procedure: quality-of-life assessment, Procedure: management of therapy complications, Behavioral: exercise intervention | Intervention Type: OTHER; Name: questionnaire administration; Assigned to Arm(s): Arm I (Control), Arm II (Exercise) | Intervention Type: PROCEDURE; Name: quality-of-life assessment; Assigned to Arm(s): Arm I (Control), Arm II (Exercise) | Intervention Type: PROCEDURE; Name: management of therapy complications; Assigned to Arm(s): Arm I (Control), Arm II (Exercise) | Intervention Type: BEHAVIORAL; Name: exercise intervention; Assigned to Arm(s): Arm II (Exercise)
C: Arm Label: Acupuncture & educ; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Acupuncture and patient education | Arm Label: 2. Standard care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Acupuncture and patient education; Assigned to Arm(s): Acupuncture & educ
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Yoga | Arm Label: 2; Type: OTHER; Interventions: Other: Delayed yoga classes | Intervention Type: BEHAVIORAL; Name: Yoga; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Delayed yoga classes; Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Yoga on Weight and Fatigue in Breast Cancer Patients Study
Brief Summary: This purpose of this study is to test whether a 6-month yoga program improves quality of life and reduces fatigue and weight gain in breast cancer survivors.


Options:
A: Arm Label: Arm I: Yoga Therapy; Type: EXPERIMENTAL; Interventions: Procedure: Yoga Therapy | Arm Label: Arm II: Wait-List; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Yoga Therapy; Assigned to Arm(s): Arm I: Yoga Therapy
B: Arm Label: Yoga Intervention (YOCAS); Type: EXPERIMENTAL; Interventions: Procedure: Yoga Intervention (YOCAS) | Arm Label: Standard Care Control Condition; Type: EXPERIMENTAL; Interventions: Procedure: Standard Care Control Condition | Intervention Type: PROCEDURE; Name: Standard Care Control Condition; Assigned to Arm(s): Standard Care Control Condition | Intervention Type: PROCEDURE; Name: Yoga Intervention (YOCAS); Assigned to Arm(s): Yoga Intervention (YOCAS)
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Yoga | Arm Label: 2; Type: OTHER; Interventions: Other: Delayed yoga classes | Intervention Type: BEHAVIORAL; Name: Yoga; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Delayed yoga classes; Assigned to Arm(s): 2
D: Arm Label: Group I (yoga-based rehabilitation program); Type: EXPERIMENTAL; Interventions: Procedure: Quality-of-Life Assessment, Procedure: Yoga | Arm Label: Group II (standard care/control); Type: ACTIVE_COMPARATOR; Interventions: Procedure: Quality-of-Life Assessment, Procedure: Yoga | Intervention Type: PROCEDURE; Name: Quality-of-Life Assessment; Assigned to Arm(s): Group I (yoga-based rehabilitation program), Group II (standard care/control) | Intervention Type: PROCEDURE; Name: Yoga; Assigned to Arm(s): Group I (yoga-based rehabilitation program), Group II (standard care/control)

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Training During Pregnancy - Effects of Regular Exercise During Pregnancy in Prevention of Pregnancy-related Diseases and Complications During Labour. A Randomised Clinical Trial
Brief Summary: There is a great lack of results from randomized clinical trials with high methodological quality, assessing the effects of exercise during pregnancy. The main aims of this trial is to study the effects of exercise during pregnancy in the prevention and treatment of disease and complications which may arise during pregnancy:

* Does regular exercise during pregnancy aid in preventing gestational diabetes?
* Does regular exercise during pregnancy prevent low back and/or pelvic girdle pain?
* Does regular exercise during pregnancy prevent urine and/or fecal incontinence?
* Does regular exercise during pregnancy have an effect on labour and delivery?
* Does regular exercise during pregnancy prevent maternal excessive weight gain and fetal macrosomatia?


Options:
A: Arm Label: stabilization exercises; Type: EXPERIMENTAL; Interventions: Other: Stabilization exercise | Arm Label: control group; Type: EXPERIMENTAL; Interventions: Other: Control group | Intervention Type: OTHER; Name: Stabilization exercise; Assigned to Arm(s): stabilization exercises | Intervention Type: OTHER; Name: Control group; Assigned to Arm(s): control group
B: Arm Label: exercise; Type: EXPERIMENTAL; Interventions: Behavioral: specific training program | Arm Label: control; Type: ACTIVE_COMPARATOR; Interventions: Other: standard | Intervention Type: OTHER; Name: standard; Assigned to Arm(s): control | Intervention Type: BEHAVIORAL; Name: specific training program; Assigned to Arm(s): exercise
C: Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Exercise Group; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise Group | Intervention Type: BEHAVIORAL; Name: Exercise Group; Assigned to Arm(s): Exercise Group
D: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Exercise group; Type: EXPERIMENTAL; Interventions: Behavioral: A supervised physical exercise program | Intervention Type: BEHAVIORAL; Name: A supervised physical exercise program; Assigned to Arm(s): Exercise group

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Training During Pregnancy - Effects of Regular Exercise During Pregnancy in Prevention of Pregnancy-related Diseases and Complications During Labour. A Randomised Clinical Trial
Brief Summary: There is a great lack of results from randomized clinical trials with high methodological quality, assessing the effects of exercise during pregnancy. The main aims of this trial is to study the effects of exercise during pregnancy in the prevention and treatment of disease and complications which may arise during pregnancy:

* Does regular exercise during pregnancy aid in preventing gestational diabetes?
* Does regular exercise during pregnancy prevent low back and/or pelvic girdle pain?
* Does regular exercise during pregnancy prevent urine and/or fecal incontinence?
* Does regular exercise during pregnancy have an effect on labour and delivery?
* Does regular exercise during pregnancy prevent maternal excessive weight gain and fetal macrosomatia?


Options:
A: Arm Label: myo-inositol; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: myo-inositol | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: folic acid 400 mcg | Intervention Type: DIETARY_SUPPLEMENT; Name: myo-inositol; Assigned to Arm(s): myo-inositol | Intervention Type: OTHER; Name: folic acid 400 mcg; Assigned to Arm(s): placebo
B: N/A
C: Arm Label: exercise; Type: EXPERIMENTAL; Interventions: Behavioral: specific training program | Arm Label: control; Type: ACTIVE_COMPARATOR; Interventions: Other: standard | Intervention Type: OTHER; Name: standard; Assigned to Arm(s): control | Intervention Type: BEHAVIORAL; Name: specific training program; Assigned to Arm(s): exercise
D: Arm Label: Myo-inositol powder; Type: EXPERIMENTAL; Interventions: Dietary Supplement: inositol + folic acid | Arm Label: Myo-inositol soft gel capsules; Type: EXPERIMENTAL; Interventions: Dietary Supplement: inositol + folic acid | Arm Label: Folic acid; Type: PLACEBO_COMPARATOR; Interventions: Drug: Folic Acid | Intervention Type: DIETARY_SUPPLEMENT; Name: inositol + folic acid; Assigned to Arm(s): Myo-inositol powder | Intervention Type: DIETARY_SUPPLEMENT; Name: inositol + folic acid; Assigned to Arm(s): Myo-inositol soft gel capsules | Intervention Type: DRUG; Name: Folic Acid; Assigned to Arm(s): Folic acid

Answer: C